Akero Therapeutics Inc (NASDAQ: AKRO) on Monday, plunged -4.09% from the previous trading day, before settling in for the closing price of $34.45. Within the past 52 weeks, AKRO’s price has moved between $13.39 and $37.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -34.90%. With a float of $58.11 million, this company’s outstanding shares have now reached $69.43 million.
Let’s determine the extent of company efficiency that accounts for 56 employees. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Akero Therapeutics Inc is 16.30%, while institutional ownership is 99.39%. The most recent insider transaction that took place on Nov 06 ’24, was worth 351,890. In this transaction Chief Development Officer of this company sold 10,000 shares at a rate of $35.19, taking the stock ownership to the 74,158 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Officer proposed sale 10,000 for $32.74, making the entire transaction worth $327,400.
Akero Therapeutics Inc (AKRO) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.99 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.86) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.90% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Akero Therapeutics Inc (AKRO) is currently performing well based on its current performance indicators. A quick ratio of 17.25 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.17 in the next quarter and is forecasted to reach -4.51 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Looking closely at Akero Therapeutics Inc (NASDAQ: AKRO), its last 5-days average volume was 0.66 million, which is a drop from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 71.17%. Additionally, its Average True Range was 1.63.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 80.92%, which indicates a significant increase from 62.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.32% in the past 14 days, which was higher than the 48.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.14, while its 200-day Moving Average is $24.95. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $34.53. Second resistance stands at $36.03. The third major resistance level sits at $36.95. If the price goes on to break the first support level at $32.12, it is likely to go to the next support level at $31.20. Should the price break the second support level, the third support level stands at $29.70.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
Market capitalization of the company is 2.27 billion based on 69,431K outstanding shares. Right now, sales total 0 K and income totals -151,760 K. The company made 0 K in profit during its latest quarter, and -55,990 K in sales during its previous quarter.
